Syndax Pharmaceuticals (NASDAQ:SNDX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $41.00 target price on the stock.

A number of other research analysts have also recently weighed in on the stock. Scotiabank cut shares of Syndax Pharmaceuticals from a sector outperform rating to a sector perform rating and dropped their price objective for the stock from $36.00 to $23.00 in a research note on Wednesday, January 31st. Mizuho initiated coverage on shares of Syndax Pharmaceuticals in a research note on Friday, December 22nd. They set a buy rating and a $45.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an overweight rating in a research note on Wednesday, March 20th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals to a sell rating in a research note on Friday, January 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $34.42.

Syndax Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ:SNDX opened at $23.80 on Wednesday. The company has a market cap of $2.02 billion, a P/E ratio of -8.04 and a beta of 1.03. Syndax Pharmaceuticals has a 52 week low of $11.22 and a 52 week high of $25.34. The company has a 50-day moving average price of $22.45 and a 200 day moving average price of $18.63.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same quarter in the prior year, the business posted ($0.62) EPS. Analysts expect that Syndax Pharmaceuticals will post -3.7 EPS for the current year.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 97.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock valued at $26,000 after buying an additional 880 shares during the period. CWM LLC grew its stake in shares of Syndax Pharmaceuticals by 415.3% during the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after buying an additional 1,358 shares during the period. MeadowBrook Investment Advisors LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 4th quarter valued at $37,000. Point72 Hong Kong Ltd acquired a new position in shares of Syndax Pharmaceuticals during the 1st quarter valued at $41,000. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Syndax Pharmaceuticals by 158.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after acquiring an additional 1,496 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).